Pay in 4 interest-free payments of $7.42 Learn more
Ships within 48 hours · Estimated delivery Sep 26 - Oct 1
Always consult with your primary care physician or our clinical partners at Celia Health to undergo proper medical screening before beginning any peptide therapy
This is clinically relevant because obesity itself is associated with numerous health conditions that might influence treatment tolerance, including metabolic syndrome, cardiovascular disease, sleep apnea, and hepatic steatosis
Absolute Contraindications BPC-157 is not recommended for patients with: Active cancer (any type) theoretical concern regarding angiogenesis promotion Pregnancy or breastfeeding insufficient safety data Known hypersensitivity to any component of the formulation Relative Contraindications (Require Individualized Assessment) History of cancer after completion of treatment, a waiting period and oncology clearance may be appropriate Autoimmune disease especially if active or requiring immunosuppressive therapy Anticoagulant use injection site bleeding risk, though minimal with proper technique Severe renal or hepatic impairment dosing adjustments may be needed Monitoring and Follow-Up Patients on BPC-157 protocols are monitored through: Baseline and follow-up labs including inflammatory markers (CRP, ESR), complete blood count, and metabolic panel Clinical assessments pain scores, range of motion, functional outcomes at 2-week, 4-week, and 8-week intervals Imaging when indicated repeat ultrasound or MRI for musculoskeletal conditions to document structural healing The Patient Journey: What to Expect For patients considering peptide therapy, understanding the timeline of response helps set realistic expectations
According to company materials, the company describes its manufacturing as occurring in FDA-registered, GMP-certified facilities in the United States, adhering to what the company characterizes as pharmaceutical-grade production standards even for dietary supplements
